Consonance Capital Management’s UroGen Pharma URGN Stock Holding History

Consonance Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,433,774	Closed	-$51.5M	–	34
2019 Q2	$51.5M	Sell	1,433,774 -325,550	-19%	-$12M	3.65%	10
2019 Q1	$65M	Buy	1,759,324 +243,902	+16%	+$10.2M	4.1%	11
2018 Q4	$65.3M	Hold	1,515,422	–	–	4.8%	10
2018 Q3	$71.6M	Buy	1,515,422 +27,931	+2%	+$1.3M	3.85%	14
2018 Q2	$74M	Buy	1,487,491 +341,294	+30%	+$19.9M	4.77%	8
2018 Q1	$57M	Buy	1,146,197 +229,747	+25%	+$11.5M	5.2%	8
2017 Q4	$34.1M	Buy	+916,450	New	+$32.6M	3.08%	14

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

HCM

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Consonance Capital Management's URGN Position: Q3 2019 in Review

Consonance Capital Management sold out of UroGen Pharma (URGN) in Q3 2019, closing a stake of 1,433,774 shares — an estimated $51.5M sold.

Consonance Capital Management first reported a position in URGN in Q4 2017 and held it in 7 quarters. The position peaked at $74M in Q2 2018. 84 funds tracked by Wall St. Rank hold URGN as of Q3 2019.

Consonance Capital Management reported no remaining UroGen Pharma position as of Q3 2019 after selling out during the quarter.
Consonance Capital Management sold 1,433,774 UroGen Pharma shares in Q3 2019, an estimated $51.5M.
Consonance Capital Management first reported a position in UroGen Pharma in Q4 2017 and held it in 7 quarters.
Consonance Capital Management's UroGen Pharma position peaked at $74M in Q2 2018.
84 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2019.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.